{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:32:57Z","timestamp":1793082777743,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejphar.2026.179417","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:08:28Z","timestamp":1791846508000},"page":"179417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Population pharmacokinetic modeling of idarubicin and idarubicinol in acute myeloid leukemia induction therapy: An ancillary study of the BIG-1 trial"],"prefix":"10.1016","volume":"1037","author":[{"given":"Stanislas","family":"Maisonneuve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-1544","authenticated-orcid":false,"given":"Guillaume","family":"Drevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Giltat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Thepot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-5998","authenticated-orcid":false,"given":"Marie","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Abbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179417_bib1","year":"2024"},{"key":"10.1016\/j.ejphar.2026.179417_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4236\/pp.2014.54054","article-title":"Population pharmacokinetic pharmacodynamic modeling of caffeine using visual analogue scales","volume":"5","author":"Burns","year":"2014","journal-title":"Pharmacol. Pharm."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179417_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00280-004-0775-4","article-title":"Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)","volume":"54","author":"Callies","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179417_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-002-0542-3","article-title":"A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)","volume":"51","author":"Callies","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179417_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00686301","article-title":"Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study","volume":"30","author":"Camaggi","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179417_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1040-8428(03)00120-3","article-title":"New oral drugs in older patients: a review of idarubicin in elderly patients","volume":"49","author":"Crivellari","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179417_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00257158","article-title":"Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin","volume":"1","author":"Di Marco","year":"1978","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179417_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.179417_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102322","article-title":"Metabolic crosstalk between thermogenic adipocyte and cancer cell: dysfunction and therapeutics","volume":"68","author":"Dong","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179417_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/pharmaceutics14040792","article-title":"Daunorubicin and its active metabolite pharmacokinetic profiles in acute myeloid leukaemia patients: a pharmacokinetic ancillary study of the BIG-1 trial","volume":"5;14","author":"Drevin","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179417_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00001813-199701000-00005","article-title":"Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course","volume":"8","author":"Eksborg","year":"1997","journal-title":"Anti Cancer Drugs"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179417_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2125.1987.tb03049.x","article-title":"Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer","volume":"23","author":"Gillies","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179417_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10637-017-0443-2","article-title":"Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents","volume":"35","author":"Piska","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejphar.2026.179417_bib14","first-page":"43","article-title":"Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML \u2013 the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups","volume":"vol. 146","author":"Recher","year":"2025"},{"issue":"20","key":"10.1016\/j.ejphar.2026.179417_bib15","first-page":"6525","article-title":"Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens cancer study group report","volume":"15;50","author":"Reid","year":"1990","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179417_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199324040-00002","article-title":"Clinical pharmacokinetics of idarubicin","volume":"24","author":"Robert","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179417_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF00254566","article-title":"Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin","volume":"19","author":"Smith","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179417_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00280-006-0332-4","article-title":"High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study","volume":"59","author":"Tedeschi","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179417_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<129::AID-IJC21>3.0.CO;2-8","article-title":"Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines","volume":"3;67","author":"Toffoli","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179417_bib20","series-title":"Bioanalytical Method Validation: Guidance for Industry","year":"2018"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179417_bib21","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.cmet.2021.08.012","article-title":"The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy","volume":"5;33","author":"Wei","year":"2021","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179417_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.leu.2401058","article-title":"A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia","volume":"12","author":"Weiss","year":"1998","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.ejphar.2026.179417_bib23","doi-asserted-by":"crossref","first-page":"14196","DOI":"10.1002\/cam4.6086","article-title":"Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory\/resistant ovarian cancer","volume":"12","author":"Yoshida","year":"2023","journal-title":"Cancer Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600899X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600899X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:37:22Z","timestamp":1793079442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992600899X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"alternative-id":["S001429992600899X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179417","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic modeling of idarubicin and idarubicinol in acute myeloid leukemia induction therapy: An ancillary study of the BIG-1 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179417"}}